Akso Health Group Form 6-K Summary
Business Context and Reporting Period
Akso Health Group, a foreign private issuer headquartered in Qingdao, China, filed this Form 6-K on February 10, 2026. The filing provides unaudited interim consolidated financial statements for the six-month period ended September 30, 2025, and includes an Operating and Financial Review and Prospects.
Key Financial Metrics
The provided text serves as a cover page and index for the financial statements. It does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the attached exhibits (Exhibit 99.1 and 99.2) which are referenced but not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. The document indicates that a comparative review for the six months ended September 30, 2024, and 2025 is available in Exhibit 99.2.
Guidance, Outlook, and Risks
Management commentary, outlook, and risk factors are contained within Exhibit 99.2 (Operating and Financial Review and Prospects). The cover text does not disclose specific guidance, contingencies, or unusual items.
Investor Verification Checklist
- Review Exhibit 99.1 for the actual unaudited interim consolidated financial statements to verify revenue and profit figures.
- Examine Exhibit 99.2 for management's discussion on operational performance and future prospects.
- Confirm the incorporation of this filing into the Company's Form S-8 (Registration No. 333-223951) and Form F-3 (Registration No. 277351).
- Verify the signature authority of Yilin (Linda) Wang, Chief Executive Officer, dated February 10, 2026.